Company Quick10K Filing
Quick10K
Catalent
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$45.21 146 $6,590
10-Q 2019-03-31 Quarter: 2019-03-31
10-Q 2018-12-31 Quarter: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-K 2018-06-30 Annual: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-Q 2017-12-31 Quarter: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-K 2017-06-30 Annual: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-Q 2016-12-31 Quarter: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-K 2016-06-30 Annual: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-Q 2015-12-31 Quarter: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-K 2015-06-30 Annual: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-Q 2014-12-31 Quarter: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-K 2014-06-30 Annual: 2014-06-30
8-K 2019-06-27 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-06-24 Regulation FD, Exhibits
8-K 2019-06-24 Other Events, Exhibits
8-K 2019-05-16 Enter Agreement, M&A, Off-BS Arrangement, Sale of Shares, Shareholder Rights, Officers, Amend Bylaw, Regulation FD, Exhibits
8-K 2019-05-07 Earnings, Exhibits
8-K 2019-04-14 Enter Agreement, Sale of Shares, Officers, Regulation FD, Exhibits
8-K 2019-03-29
8-K 2019-02-13 Regulation FD, Exhibits
8-K 2019-02-05 Earnings, Exhibits
8-K 2018-10-31 Earnings, Shareholder Rights, Officers, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-08-28 Earnings, Exhibits
8-K 2018-08-14 Other Events, Exhibits
8-K 2018-07-24 Enter Agreement, Exhibits
8-K 2018-07-24 Other Events, Exhibits
8-K 2018-07-23 Earnings, Regulation FD, Exhibits
8-K 2018-07-23 Other Events, Exhibits
8-K 2018-07-02 Other Events, Exhibits
8-K 2018-02-16 Officers, Exhibits
8-K 2018-01-09 Officers
NOK Nokia 27,710
TRVG Trivago 1,510
EVI Envirostar 420
CNSL Consolidated Communications Holdings 358
IRMD Iradimed 262
IPIC iPic 47
CCCL China Ceramics 7
SING Singlepoint 0
RSRT Realsource Residential 0
CTAM Castle A M 0
CTLT 2019-03-31
Part I. Financial Information
Item 1. Financial Statements
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
Part II. Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Mine Safety Disclosures
Item 5. Other Information
Item 6. Exhibits
EX-10.40 catalent-2019331xex1040.htm
EX-10.41 catalent-2019331xex1041.htm
EX-10.42 catalent-2019331xex1042.htm
EX-10.43 catalent-2019331xex1043.htm
EX-10.44 catalent-2019331xex1044.htm
EX-10.45 catalent-2019331xex1045.htm
EX-31.1 catalent-2019331xex311.htm
EX-31.2 catalent-2019331xex312.htm
EX-32.1 catalent-2019331xex321.htm
EX-32.2 catalent-2019331xex322.htm

Catalent Earnings 2019-03-31

CTLT 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

Document
FALSEMarch 31, 20192019Q3Catalent, Inc.--06-30Large Accelerated FilerFALSEFALSE00015967830.010.011,000,000,0001,000,000,000145,221,009133,423,628145,221,009133,423,6280.010.01100,000,000100,000,00000015967832018-07-012019-03-31xbrli:shares00015967832019-05-03iso4217:USD00015967832019-01-012019-03-3100015967832018-01-012018-03-3100015967832017-07-012018-03-31iso4217:USDxbrli:shares00015967832019-03-3100015967832018-06-300001596783us-gaap:CommonStockMember2018-12-310001596783us-gaap:AdditionalPaidInCapitalMember2018-12-310001596783us-gaap:RetainedEarningsMember2018-12-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-3100015967832018-12-310001596783us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310001596783us-gaap:CommonStockMember2019-01-012019-03-310001596783us-gaap:RetainedEarningsMember2019-01-012019-03-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310001596783us-gaap:CommonStockMember2019-03-310001596783us-gaap:AdditionalPaidInCapitalMember2019-03-310001596783us-gaap:RetainedEarningsMember2019-03-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310001596783us-gaap:CommonStockMember2017-12-310001596783us-gaap:AdditionalPaidInCapitalMember2017-12-310001596783us-gaap:RetainedEarningsMember2017-12-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-3100015967832017-12-310001596783us-gaap:CommonStockMember2018-01-012018-03-310001596783us-gaap:AdditionalPaidInCapitalMember2018-01-012018-03-310001596783us-gaap:RetainedEarningsMember2018-01-012018-03-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-03-310001596783us-gaap:CommonStockMember2018-03-310001596783us-gaap:AdditionalPaidInCapitalMember2018-03-310001596783us-gaap:RetainedEarningsMember2018-03-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-03-3100015967832018-03-310001596783us-gaap:CommonStockMember2018-06-300001596783us-gaap:AdditionalPaidInCapitalMember2018-06-300001596783us-gaap:RetainedEarningsMember2018-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-300001596783us-gaap:RetainedEarningsMember2018-07-012019-03-310001596783us-gaap:CommonStockMember2018-07-012019-03-310001596783us-gaap:AdditionalPaidInCapitalMember2018-07-012019-03-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-07-012019-03-310001596783us-gaap:CommonStockMember2017-06-300001596783us-gaap:AdditionalPaidInCapitalMember2017-06-300001596783us-gaap:RetainedEarningsMember2017-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-06-3000015967832017-06-300001596783us-gaap:CommonStockMember2017-07-012018-03-310001596783us-gaap:AdditionalPaidInCapitalMember2017-07-012018-03-310001596783us-gaap:RetainedEarningsMember2017-07-012018-03-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-07-012018-03-310001596783us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-03-310001596783us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-07-012019-03-310001596783us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-01-012018-03-310001596783us-gaap:SellingGeneralAndAdministrativeExpensesMember2017-07-012018-03-310001596783us-gaap:CostOfSalesMember2019-01-012019-03-310001596783us-gaap:CostOfSalesMember2018-07-012019-03-310001596783us-gaap:CostOfSalesMember2018-01-012018-03-310001596783us-gaap:CostOfSalesMember2017-07-012018-03-310001596783us-gaap:AccountingStandardsUpdate201409Member2018-07-012019-03-310001596783us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2019-01-012019-03-310001596783us-gaap:AccountingStandardsUpdate201409Memberus-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member2019-01-012019-03-310001596783us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2018-07-012019-03-310001596783us-gaap:AccountingStandardsUpdate201409Memberus-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member2018-07-012019-03-310001596783us-gaap:AccountingStandardsUpdate201707Member2018-07-012019-03-310001596783us-gaap:AccountingStandardsUpdate201707Membersrt:ScenarioPreviouslyReportedMember2018-01-012018-03-310001596783us-gaap:AccountingStandardsUpdate201707Membersrt:ScenarioPreviouslyReportedMember2017-07-012018-03-310001596783us-gaap:ProductAndServiceOtherMember2018-07-012019-03-310001596783ctlt:ManufacturingCommercialProductSupplyMemberctlt:SoftgelTechnologiesMember2019-01-012019-03-310001596783ctlt:BiologicsandSpecialtyDrugDeliveryMemberctlt:ManufacturingCommercialProductSupplyMember2019-01-012019-03-310001596783ctlt:OralDrugDeliveryMemberctlt:ManufacturingCommercialProductSupplyMember2019-01-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:ManufacturingCommercialProductSupplyMember2019-01-012019-03-310001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMemberctlt:ManufacturingCommercialProductSupplyMember2019-01-012019-03-310001596783ctlt:DevelopmentServicesMemberctlt:SoftgelTechnologiesMember2019-01-012019-03-310001596783ctlt:BiologicsandSpecialtyDrugDeliveryMemberctlt:DevelopmentServicesMember2019-01-012019-03-310001596783ctlt:DevelopmentServicesMemberctlt:OralDrugDeliveryMember2019-01-012019-03-310001596783ctlt:DevelopmentServicesMemberctlt:ClinicalSupplyServicesMember2019-01-012019-03-310001596783ctlt:DevelopmentServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2019-01-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:SoftgelTechnologiesMember2019-01-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:BiologicsandSpecialtyDrugDeliveryMember2019-01-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:OralDrugDeliveryMember2019-01-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:ClinicalSupplyServicesMember2019-01-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2019-01-012019-03-310001596783ctlt:SoftgelTechnologiesMember2019-01-012019-03-310001596783ctlt:BiologicsandSpecialtyDrugDeliveryMember2019-01-012019-03-310001596783ctlt:OralDrugDeliveryMember2019-01-012019-03-310001596783ctlt:ClinicalSupplyServicesMember2019-01-012019-03-310001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2019-01-012019-03-310001596783ctlt:ManufacturingCommercialProductSupplyMemberctlt:SoftgelTechnologiesMember2018-07-012019-03-310001596783ctlt:BiologicsandSpecialtyDrugDeliveryMemberctlt:ManufacturingCommercialProductSupplyMember2018-07-012019-03-310001596783ctlt:OralDrugDeliveryMemberctlt:ManufacturingCommercialProductSupplyMember2018-07-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:ManufacturingCommercialProductSupplyMember2018-07-012019-03-310001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMemberctlt:ManufacturingCommercialProductSupplyMember2018-07-012019-03-310001596783ctlt:DevelopmentServicesMemberctlt:SoftgelTechnologiesMember2018-07-012019-03-310001596783ctlt:BiologicsandSpecialtyDrugDeliveryMemberctlt:DevelopmentServicesMember2018-07-012019-03-310001596783ctlt:DevelopmentServicesMemberctlt:OralDrugDeliveryMember2018-07-012019-03-310001596783ctlt:DevelopmentServicesMemberctlt:ClinicalSupplyServicesMember2018-07-012019-03-310001596783ctlt:DevelopmentServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2018-07-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:SoftgelTechnologiesMember2018-07-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:BiologicsandSpecialtyDrugDeliveryMember2018-07-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:OralDrugDeliveryMember2018-07-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:ClinicalSupplyServicesMember2018-07-012019-03-310001596783ctlt:ClinicalSupplyServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2018-07-012019-03-310001596783ctlt:SoftgelTechnologiesMember2018-07-012019-03-310001596783ctlt:BiologicsandSpecialtyDrugDeliveryMember2018-07-012019-03-310001596783ctlt:OralDrugDeliveryMember2018-07-012019-03-310001596783ctlt:ClinicalSupplyServicesMember2018-07-012019-03-310001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2018-07-012019-03-310001596783ctlt:geographicalMember2018-07-012019-03-310001596783srt:NorthAmericaMember2019-01-012019-03-310001596783srt:NorthAmericaMember2018-07-012019-03-310001596783srt:EuropeMember2019-01-012019-03-310001596783srt:EuropeMember2018-07-012019-03-310001596783ctlt:InternationalOtherMember2019-01-012019-03-310001596783ctlt:InternationalOtherMember2018-07-012019-03-310001596783ctlt:ClinicalSupplyServicesMember2019-03-31xbrli:pure00015967832018-08-142018-08-140001596783ctlt:ProductRelationshipsMember2018-08-142018-08-140001596783us-gaap:CustomerRelationshipsMember2018-08-142018-08-140001596783ctlt:SoftgelTechnologiesMember2018-06-300001596783ctlt:BiologicsandSpecialtyDrugDeliveryMember2018-06-300001596783ctlt:OralDrugDeliveryMember2018-06-300001596783ctlt:ClinicalSupplyServicesMember2018-06-300001596783ctlt:SoftgelTechnologiesMember2019-03-310001596783ctlt:BiologicsandSpecialtyDrugDeliveryMember2019-03-310001596783ctlt:OralDrugDeliveryMember2019-03-310001596783ctlt:CoreTechnologyMember2018-07-012019-03-310001596783ctlt:CoreTechnologyMember2019-03-310001596783us-gaap:CustomerRelationshipsMember2018-07-012019-03-310001596783us-gaap:CustomerRelationshipsMember2019-03-310001596783ctlt:ProductRelationshipsMember2018-07-012019-03-310001596783ctlt:ProductRelationshipsMember2019-03-310001596783ctlt:CoreTechnologyMember2017-07-012018-06-300001596783ctlt:CoreTechnologyMember2018-06-300001596783us-gaap:CustomerRelationshipsMember2017-07-012018-06-300001596783us-gaap:CustomerRelationshipsMember2018-06-300001596783ctlt:ProductRelationshipsMember2017-07-012018-06-300001596783ctlt:ProductRelationshipsMember2018-06-300001596783ctlt:TermLoanThreeFacilityDollarDenominatedMember2019-03-310001596783ctlt:TermLoanThreeFacilityDollarDenominatedMember2018-06-300001596783ctlt:TermLoanThreeFacilityEuroDenominatedMember2019-03-310001596783ctlt:TermLoanThreeFacilityEuroDenominatedMember2018-06-300001596783ctlt:FourPointSevenFivePercentSeniorEuroDenominatedNotesMember2019-03-310001596783ctlt:FourPointSevenFivePercentSeniorEuroDenominatedNotesMember2018-06-300001596783ctlt:U.S.Dollardenominated4.875SeniorNotesMember2019-03-310001596783ctlt:U.S.Dollardenominated4.875SeniorNotesMember2018-06-300001596783us-gaap:RevolvingCreditFacilityMember2019-03-310001596783us-gaap:RevolvingCreditFacilityMember2018-06-300001596783ctlt:RevolvingCreditFacilityTwoMember2019-03-310001596783ctlt:RevolvingCreditFacilityTwoMember2018-06-300001596783us-gaap:CapitalLeaseObligationsMember2019-03-310001596783us-gaap:CapitalLeaseObligationsMember2018-06-300001596783ctlt:OtherObligationsMember2019-03-310001596783ctlt:OtherObligationsMember2018-06-300001596783us-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMemberctlt:TermLoanThreeFacilityDollarDenominatedMember2019-03-310001596783us-gaap:LondonInterbankOfferedRateLIBORMemberctlt:TermLoanThreeFacilityDollarDenominatedMember2018-07-012019-03-310001596783us-gaap:LondonInterbankOfferedRateLIBORMemberctlt:TermLoanThreeFacilityEuroDenominatedMembersrt:MinimumMember2019-03-310001596783us-gaap:LondonInterbankOfferedRateLIBORMemberctlt:TermLoanThreeFacilityEuroDenominatedMember2018-07-012019-03-310001596783ctlt:RevolvingCreditFacilityTwoMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MaximumMember2018-07-012019-03-310001596783ctlt:RevolvingCreditFacilityTwoMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMember2018-07-012019-03-310001596783ctlt:TermLoanThreeFacilityDollarDenominatedMember2018-07-312018-07-31iso4217:EUR0001596783ctlt:FourPointSevenFivePercentSeniorEuroDenominatedNotesMember2016-12-090001596783ctlt:U.S.Dollardenominated4.875SeniorNotesMember2017-10-180001596783ctlt:DeferredPurchaseConsiderationMember2017-10-232017-10-230001596783us-gaap:AccruedLiabilitiesMemberctlt:DeferredPurchaseConsiderationMember2017-10-232017-10-230001596783ctlt:DeferredPurchaseConsiderationMember2019-03-310001596783us-gaap:BridgeLoanMember2017-09-180001596783us-gaap:BridgeLoanMember2017-09-300001596783us-gaap:BridgeLoanMember2017-10-170001596783us-gaap:FairValueInputsLevel1Memberctlt:FourPointSevenFivePercentSeniorEuroDenominatedNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2019-03-310001596783us-gaap:FairValueInputsLevel1Memberctlt:FourPointSevenFivePercentSeniorEuroDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2019-03-310001596783us-gaap:FairValueInputsLevel1Memberctlt:FourPointSevenFivePercentSeniorEuroDenominatedNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2018-06-300001596783us-gaap:FairValueInputsLevel1Memberctlt:FourPointSevenFivePercentSeniorEuroDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2018-06-300001596783us-gaap:FairValueInputsLevel1Memberctlt:U.S.Dollardenominated4.875SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2019-03-310001596783us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberctlt:U.S.Dollardenominated4.875SeniorNotesMember2019-03-310001596783us-gaap:FairValueInputsLevel1Memberctlt:U.S.Dollardenominated4.875SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2018-06-300001596783us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberctlt:U.S.Dollardenominated4.875SeniorNotesMember2018-06-300001596783ctlt:SeniorSecuredCreditFacilitiesOtherMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2019-03-310001596783us-gaap:EstimateOfFairValueFairValueDisclosureMemberctlt:SeniorSecuredCreditFacilitiesOtherMemberus-gaap:FairValueInputsLevel2Member2019-03-310001596783ctlt:SeniorSecuredCreditFacilitiesOtherMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2018-06-300001596783us-gaap:EstimateOfFairValueFairValueDisclosureMemberctlt:SeniorSecuredCreditFacilitiesOtherMemberus-gaap:FairValueInputsLevel2Member2018-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMember2019-03-310001596783us-gaap:EstimateOfFairValueFairValueDisclosureMember2019-03-310001596783us-gaap:CarryingReportedAmountFairValueDisclosureMember2018-06-300001596783us-gaap:EstimateOfFairValueFairValueDisclosureMember2018-06-300001596783ctlt:EmployeeStockOptionsandRSUsMember2019-01-012019-03-310001596783ctlt:EmployeeStockOptionsandRSUsMember2018-07-012019-03-310001596783ctlt:EmployeeStockOptionsandRSUsMember2018-01-012018-03-310001596783ctlt:EmployeeStockOptionsandRSUsMember2017-07-012018-03-310001596783us-gaap:EmployeeSeveranceMember2019-01-012019-03-310001596783us-gaap:EmployeeSeveranceMember2018-01-012018-03-310001596783us-gaap:EmployeeSeveranceMember2018-07-012019-03-310001596783us-gaap:EmployeeSeveranceMember2017-07-012018-03-310001596783ctlt:BusinessExitCostsMember2019-01-012019-03-310001596783ctlt:BusinessExitCostsMember2018-01-012018-03-310001596783ctlt:BusinessExitCostsMember2018-07-012019-03-310001596783ctlt:BusinessExitCostsMember2017-07-012018-03-310001596783ctlt:EuroDenominatedDebtOutstandingMember2019-03-310001596783ctlt:FormerOwnerMember2019-03-310001596783ctlt:FormerOwnerMember2018-06-3000015967832018-07-272018-07-2700015967832018-07-2700015967832017-09-292017-09-2900015967832017-09-290001596783us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-12-310001596783us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-03-310001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-03-310001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-03-310001596783us-gaap:AccumulatedTranslationAdjustmentMember2019-03-310001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-03-310001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-03-310001596783us-gaap:AccumulatedTranslationAdjustmentMember2018-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-06-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-06-3000015967832018-09-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2018-07-012019-03-310001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-07-012019-03-310001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-07-012019-03-310001596783ctlt:SoftgelTechnologiesMember2018-01-012018-03-310001596783ctlt:SoftgelTechnologiesMember2017-07-012018-03-310001596783ctlt:BiologicsandSpecialtyDrugDeliveryMember2018-01-012018-03-310001596783ctlt:BiologicsandSpecialtyDrugDeliveryMember2017-07-012018-03-310001596783ctlt:OralDrugDeliveryMember2018-01-012018-03-310001596783ctlt:OralDrugDeliveryMember2017-07-012018-03-310001596783ctlt:ClinicalSupplyServicesMember2018-01-012018-03-310001596783ctlt:ClinicalSupplyServicesMember2017-07-012018-03-310001596783ctlt:CorporateAndEliminationsMember2019-03-310001596783ctlt:CorporateAndEliminationsMember2018-06-300001596783us-gaap:SubsequentEventMember2019-04-012019-05-070001596783us-gaap:SubsequentEventMember2019-04-15
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________
FORM 10-Q 
______________________________ 
ýQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2019 
or
¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
001-36587
(Commission File Number)
 _____________________________
Catalent, Inc.
(Exact name of registrant as specified in its charter)
_____________________________ 
Delaware 20-8737688
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
14 Schoolhouse Road, Somerset, NJ 08873
(Address of principal executive offices) (Zip code)
(732) 537-6200
Registrant's telephone number, including area code
______________________________ 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.           x Yes ¨  No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).            x Yes ¨  No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
Accelerated filer ¨
Non-accelerated filer ¨
Smaller reporting company ¨
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     ¨ Yes    x No 

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbols(s)
Name of each exchange on which registered
Common Stock
CTLT
New York Stock Exchange

On May 3, 2019, there were 145,715,171 shares of the Registrant's common stock, par value $0.01 per share, issued and outstanding.



Table of Contents


Table of Contents
CATALENT, INC. and Subsidiaries

INDEX TO FORM 10-Q
For the Three and Nine Months Ended March 31, 2019 
 
ItemPage
Part I.
Item 1.
Item 2.
Item 3.
Item 4.
Part II.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.

3

Table of Contents
Special Note Regarding Forward-Looking Statements
In addition to historical information, this Quarterly Report on Form 10-Q may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words.
These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Any forward-looking statement is subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.
Some of the factors that may cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements include, but are not limited to, those described under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2018 (the "Fiscal 2018 10-K") and the following:

We participate in a highly competitive market, and increased competition may adversely affect our business.

The demand for our offerings depends in part on our customers’ research and development and the clinical and market success of their products. Our business, financial condition, and results of operations may be harmed if our customers spend less on, or are less successful in, these activities.

We are subject to product and other liability risks that could exceed our anticipated costs or adversely affect our results of operations, financial condition, liquidity, and cash flows.

Failure to comply with existing and future regulatory requirements could adversely affect our results of operations and financial condition or result in claims from customers.

Failure to provide quality offerings to our customers could have an adverse effect on our business and subject us to regulatory actions or costly litigation.

The services and offerings we provide are highly exacting and complex, and if we encounter problems providing the services or support required, our business could suffer.

Our global operations are subject to economic, political, and regulatory risks, including the risks of changing regulatory standards or changing interpretations of existing standards, that could affect the profitability of our operations or require costly changes to our procedures.

The exit of the United Kingdom (the "U.K.") from the European Union could have future adverse effects on our operations, revenues, and costs, and therefore our profitability.

If we do not enhance our existing or introduce new technology or service offerings in a timely manner, our offerings may become obsolete over time, customers may not buy our offerings, and our revenue and profitability may decline.

We and our customers depend on patents, copyrights, trademarks, trade secrets, and other forms of intellectual property protections, but these protections may not be adequate.

Our future results of operations are subject to fluctuations in the costs, availability, and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients, purchased components, and raw materials.

Changes in market access or healthcare reimbursement for our customers’ products in the United States ("U.S.") or internationally, including possible changes to the U.S. Affordable Care Act, could adversely affect our results of operations and financial condition by affecting demand for our offerings or the financial health of our customers.

4

Table of Contents
As a global enterprise, fluctuations in the exchange rate of the U.S. dollar, our reporting currency, against foreign currencies could have a material adverse effect on our financial performance and results of operations.

Tax legislative or regulatory initiatives or challenges to our tax positions could adversely affect our results of operations and financial condition.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Changes to the estimated future profitability of the business may require that we establish an additional valuation allowance against all or some portion of our net U.S. deferred tax assets.

We are dependent on key personnel.

We use advanced information and communication systems to run our operations, compile and analyze financial and operational data, and communicate among our employees, customers, and counter-parties, and the risks generally associated with information and communications systems could adversely affect our results of operations. We are continuously working to install new, and upgrade existing, systems and provide employee awareness training around phishing, malware, and other cyber-security risks to enhance the protections available to us, but such protections may be inadequate to address malicious attacks or inadvertent compromises of data security.

We engage, from time to time, in acquisitions and other transactions, including the pending acquisition of Paragon Bioservices, Inc. (“Paragon”), that may complement or expand our business or divest of non-strategic businesses or assets. We may not be able to complete such transactions, and such transactions, if executed, pose significant risks, including risks relating to our ability to successfully and efficiently integrate acquisitions or execute on dispositions and realize anticipated benefits therefrom. The failure to execute or realize the full benefits from any such transaction could have a negative effect on our operations.

Our offerings or our customers’ products may infringe on the intellectual property rights of third parties.

We are subject to environmental, health, and safety laws and regulations, which could increase our costs and restrict our operations in the future.

We are subject to labor and employment laws and regulations, which could increase our costs and restrict our operations in the future.

Certain of our pension plans are underfunded, and additional cash contributions we may make to increase the funding level will reduce the cash available for our business, such as the payment of our interest expense.

Our substantial leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or in our industry, expose us to interest-rate risk to the extent of our variable rate debt, and prevent us from meeting our obligations under our indebtedness.

We caution you that the risks, uncertainties and other factors referenced above may not contain all of the risks, uncertainties, and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits, or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this report apply only as of the date of this report or as of the date they were made, and we undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law.
5

Table of Contents
Social Media
We use our website (www.catalent.com), our corporate Facebook page (https://www.facebook.com/CatalentPharmaSolutions), and our corporate Twitter account (@catalentpharma) as channels for the distribution of information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, Securities and Exchange Commission ("SEC") filings, and public conference calls and webcasts. The contents of our website and social media channels are not, however, a part of this report.
6

Table of Contents
PART I. FINANCIAL INFORMATION

Item 1.  FINANCIAL STATEMENTS

Catalent, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited; Dollars in millions, except per share data)

Three Months Ended  
March 31,
Nine Months Ended  
March 31,
2019201820192018
Net revenue$617.5 $627.9 $1,792.3 $1,778.1 
Cost of sales418.8 436.2 1,243.7 1,258.9 
Gross margin198.7 191.7 548.6 519.2 
Selling, general, and administrative expenses129.9 117.6 368.6 339.9 
Impairment charges and (gain)/loss on sale of assets(0.1)0.2 2.7 4.4 
Restructuring and other3.1 1.4 12.9 2.7 
Operating earnings65.8 72.5 164.4 172.2 
Interest expense, net26.4 29.9 80.0 81.4 
Other (income)/expense, net(3.2)9.9 3.9 28.2 
Earnings from continuing operations before income taxes 42.6 32.7 80.5 62.6 
Income tax expense 10.9 13.7 14.2 61.7 
Net earnings$31.7 $19.0 $66.3 $0.9 
Earnings per share: 
Basic 
Net earnings$0.22 $0.14 $0.46 $0.01 
Diluted 
Net earnings$0.22 $0.14 $0.46 $0.01 
The accompanying notes are an integral part of these unaudited consolidated financial statements.


7

Table of Contents
Catalent, Inc. and Subsidiaries
Consolidated Statements of Comprehensive Income/(Loss)
(Unaudited; Dollars in millions)

Three Months Ended  
March 31,
Nine Months Ended  
March 31,
2019201820192018
Net earnings$31.7 $19.0 $66.3 $0.9 
Other comprehensive income/(loss), net of tax
Foreign currency translation adjustments21.5 38.2 (4.9)62.9 
Pension and other post-retirement adjustments0.4 0.4 1.4 1.3 
Available for sale investments 0.7  (5.7)
Other comprehensive income/(loss), net of tax21.9 39.3 (3.5)58.5 
Comprehensive income/(loss)$53.6 $58.3 $62.8 $59.4 
The accompanying notes are an integral part of these unaudited consolidated financial statements.

8

Table of Contents
Catalent, Inc. and Subsidiaries
Consolidated Balance Sheets
(Unaudited; Dollars in millions, except share and per share data)
 
March 31,
2019
June 30,
2018
ASSETS
Current assets:
Cash and cash equivalents $227.9 $410.2 
Trade receivables, net 583.5 555.8 
Inventories247.0 209.1 
Prepaid expenses and other 85.3 65.2 
Total current assets 1,143.7 1,240.3 
Property, plant, and equipment, net 1,301.5 1,270.6 
Other assets:
Goodwill1,409.3 1,397.2 
Other intangibles, net554.4 544.9 
Deferred income taxes30.1 32.9 
Other54.1 45.2 
Total assets $4,493.1 $4,531.1 
LIABILITIES AND SHAREHOLDER’S DEFICIT
Current liabilities:  
Current portion of long-term obligations and other short-term borrowings $70.3 $71.9 
Accounts payable 202.3 192.1 
Other accrued liabilities 252.8 312.9 
Total current liabilities 525.4 576.9 
Long-term obligations, less current portion 2,116.3 2,649.4 
Pension liability128.5 131.6 
Deferred income taxes32.7 32.5 
Other liabilities69.5 54.0 
Commitment and contingencies (see Note 14)
Shareholders' equity:
Common stock $0.01 par value; 1.0 billion shares authorized on March 31, 2019 and June 30, 2018, 145,706,760 and 133,423,628 issued and outstanding on March 31, 2019 and June 30, 2018, respectively.1.5 1.3 
Preferred stock $0.01 par value; 100 million authorized on March 31, 2019 and June 30, 2018, 0 issued and outstanding on March 31, 2019 and June 30, 2018.  
Additional paid in capital2,739.2 2,283.3 
Accumulated deficit(790.7)(872.1)
Accumulated other comprehensive income/(loss)(329.3)(325.8)
Total shareholder's equity1,620.7 1,086.7 
Total liabilities and shareholder’s equity$4,493.1 $4,531.1 
The accompanying notes are an integral part of these unaudited consolidated financial statements.
9

Table of Contents
Catalent, Inc. and Subsidiaries
Consolidated Statement of Changes in Shareholders' Equity/(Deficit)
(Unaudited; Dollars in millions, except share data in thousands)
 
Three Months Ended March 31, 2019
Shares of Common Stock
Common
Stock
Additional
Paid in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Income/(Loss)
Total
Shareholders'
Equity/ (Deficit)
Balance at December 31, 2018145,622.9 $1.5 $2,735.1 $(822.4)$(351.2)$1,563.0 
Equity offering, sale of common stock (0.2)(0.2)
Share issuances related to stock-based
compensation
83.9   
Stock-based compensation6.6 6.6 
Cash paid, in lieu of equity, for tax
withholding
(2.3)(2.3)
Net earnings31.7 31.7 
Other comprehensive income/(loss), net of
tax 
21.9 21.9 
Balance at March 31, 2019145,706.8 $1.5 $2,739.2 $(790.7)$(329.3)$1,620.7 


Three Months Ended March 31, 2018
Shares of Common StockCommon StockAdditional Paid in CapitalAccumulated DeficitAccumulated Other Comprehensive Income/(Loss)Total Shareholders' Equity/ (Deficit)
Balance at December 31, 2017133,318.0 $1.3 $2,272.9 $(973.8)$(294.9)$1,005.5 
Share issuances related to stock-based
compensation
51.3   
Stock-based compensation5.6 5.6 
Cash paid, in lieu of equity, for tax
withholding
(1.0)(1.0)
Net earnings19.0 19.0 
Other comprehensive income/(loss), net of
tax 
39.3 39.3 
Balance at March 31, 2018133,369.3 $1.3 $2,277.5 $(954.8)$(255.6)$1,068.4 
The accompanying notes are an integral part of these unaudited consolidated financial statements.











10

Table of Contents
Catalent, Inc. and Subsidiaries
Consolidated Statement of Changes in Shareholders' Equity/(Deficit)
(Unaudited; Dollars in millions, except share data in thousands)
 
Nine Months ended March 31, 2019
Shares of Common StockCommon StockAdditional Paid in CapitalAccumulated DeficitAccumulated Other Comprehensive Income/(Loss)Total Shareholders' Equity/ (Deficit)
Balance at June 30, 2018133,423.6 $1.3 $2,283.3 $(872.1)$(325.8)$1,086.7 
Cumulative effect of change in accounting
 for ASC 606, net of tax
15.1 15.1 
Equity offering, sale of common stock11,431.4 0.1 445.2 445.3 
Share issuances related to stock-based
compensation
851.8 0.1 (0.1) 
Stock-based compensation24.1 24.1 
Cash paid, in lieu of equity, for tax
withholding
(13.3)(13.3)
Net earnings66.3 66.3 
Other comprehensive income/(loss), net of
tax 
(3.5)(3.5)
Balance at March 31, 2019145,706.8 $1.5 $2,739.2 $(790.7)$(329.3)$1,620.7 

Nine Months ended March 31, 2018
Shares of Common StockCommon StockAdditional Paid in CapitalAccumulated DeficitAccumulated Other Comprehensive Income/(Loss)Total Shareholders' Equity/ (Deficit)
Balance at June 30, 2017125,049.9 $1.3 $1,992.0 $(955.7)$(314.1)$723.5 
Equity offering, sale of common stock7,354.2  277.8 277.8 
Share issuances related to stock-based
compensation
965.2    
Stock-based compensation21.1 21.1 
Cash paid, in lieu of equity, for tax
withholding
(13.4)(13.4)
Net earnings0.9 0.9 
Other comprehensive income/(loss), net of
tax 
58.5 58.5 
Balance at March 31, 2018133,369.3 $1.3 $2,277.5 $(954.8)$(255.6)$1,068.4 
The accompanying notes are an integral part of these unaudited consolidated financial statements.
11

Table of Contents
Catalent, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited; Dollars in millions)

Nine Months Ended 
March 31,
20192018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings$66.3 $0.9 
Adjustments to reconcile earnings from operations to net cash from operations:
Depreciation and amortization173.9 137.5 
Non-cash foreign currency transaction (gain)/loss, net(1.7)14.3 
Amortization and write-off of debt financing costs
7.1 3.6 
Asset impairments charges and (gain)/loss on sale of assets
2.7 4.4 
Reclassification of financing fees paid
 11.8 
Stock-based compensation
24.1 21.1 
Provision/(benefit) for deferred income taxes(0.7)40.3 
Provision for bad debts and inventory10.6 4.9 
Change in operating assets and liabilities:
Decrease/(increase) in trade receivables(26.6)33.6 
Decrease/(increase) in inventories(43.1)(6.3)
Increase/(decrease) in accounts payable5.9 15.3 
Other assets/accrued liabilities, net current and non-current
(58.7)(10.2)
Net cash provided by operating activities 159.8 271.2 
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment and other productive assets(129.3)(117.7)
Proceeds from sale of property and equipment0.4 1.8 
Proceeds from sale of subsidiaries 3.4 
Payment for acquisitions, net of cash acquired (127.5)(748.0)
Payment made for investments(1.3) 
Net cash (used in) investing activities (257.7)(860.5)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net change in other borrowings (6.5)(2.6)
Proceeds from borrowing, net 442.6 
Payments related to long-term obligations(508.0)(14.2)
Financing fees paid
 (15.6)
Proceeds from sale of common stock, net 445.3 277.8 
Cash paid, in lieu of equity, for tax-withholding obligations(13.3)(13.4)
Net cash (used in)/provided by financing activities (82.5)674.6 
Effect of foreign currency exchange on cash (1.9)17.9 
NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS(182.3)103.2 
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD410.2 288.3 
CASH AND EQUIVALENTS AT END OF PERIOD$227.9 $391.5 
SUPPLEMENTARY CASH FLOW INFORMATION:
Interest paid$74.6 $57.2 
Income taxes paid, net$35.4 $8.3 

The accompanying notes are an integral part of these unaudited consolidated financial statements.
12

Table of Contents
Catalent, Inc. and Subsidiaries
Notes to Unaudited Consolidated Financial Statements

 
1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business
Catalent, Inc. ("Catalent" or the "Company") directly and wholly owns PTS Intermediate Holdings LLC ("Intermediate Holdings"). Intermediate Holdings directly and wholly owns Catalent Pharma Solutions, Inc. ("Operating Company"). The financial results of Catalent are comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis.
Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending June 30, 2019. The consolidated balance sheet at June 30, 2018 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. For further information on the Company's accounting policies and footnotes, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2018 filed with the Securities and Exchange Commission (the "SEC").
In fiscal 2018, the Company engaged in a business reorganization to better align its internal business unit structure with its "Follow the Molecule" strategy and the increased focus on its biologics-related offerings. Under the revised structure, the Company created two new operating segments from the former Drug Delivery Solutions segment:
Biologics and Specialty Drug Delivery, which encompasses biologic cell-line development and manufacturing, development and manufacturing services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; and development and manufacturing for inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays; and
Oral Drug Delivery, which encompasses comprehensive formulation development, manufacturing, and analytical development capabilities using advanced processing technologies such as bioavailability enhancement, controlled release, particle size engineering, and taste-masking for solid oral-dose forms.
Each of the two new segments reports through a separate management team and ultimately reports to the Company's Chief Executive Officer who is designated as the Chief Operating Decision Maker for segment reporting purposes. The Company's operating segments are the same as its reporting segments. All prior-period comparative segment information has been restated to reflect the current reportable segments in accordance with Accounting Standards Codification ("ASC") 280, Segment Reporting.
Foreign Currency Translation
The financial statements of the Company’s operations outside the U.S. are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign operations into U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. In June 2018, as a result of the three-year cumulative consumer price index exceeding 100%, Argentina was classified as having a highly inflationary economy. Beginning on July 1, 2018, the Company accounts for its Argentine operations as highly inflationary.
Research and Development Costs
The Company expenses research and development costs as incurred. Costs incurred in connection with the development of new offerings and manufacturing process improvements are recorded within selling, general, and administrative expenses. Such research and development costs included in selling, general, and administrative expenses amounted to $0.9 million and $2.4 million for the three and nine months ended March 31, 2019, respectively, and $1.8 million and $5.1 million for the three and nine months ended March 31, 2018, respectively. Costs incurred in connection with research and development
13

Table of Contents
services the Company provides to customers and services performed in support of the commercial manufacturing process for customers are recorded within cost of sales. Such research and development costs included in cost of sales amounted to $11.8 million and $37.4 million for the three and nine months ended March 31, 2019, respectively, and $11.2 million and $33.6 million for the three and nine months ended March 31, 2018, respectively.
Recent Financial Accounting Standards
Recently Adopted Accounting Standards
In May 2014, the Financial Accounting Standard Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers, which was codified as ASC 606 and superseded nearly all existing revenue-recognition guidance. The guidance’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, the guidance creates a five-step model that requires a company to exercise judgment when considering the terms of the contracts and all relevant facts and circumstances. The five steps require a company to identify customer contracts, identify the separate performance obligations, determine the transaction price, allocate the transaction price to the separate performance obligations, and recognize revenue when or as each performance obligation is satisfied. The guidance allows for either full retrospective adoption, where the standard is applied to all periods presented, or modified retrospective adoption, where the standard is applied only to the most current period presented in the financial statements. The Company adopted the guidance as of July 1, 2018 using the modified retrospective approach applied to contracts that were not completed as of that date. The Company recorded a cumulative effect adjustment to the fiscal 2019 opening balance of its accumulated deficit upon adoption of this guidance, which decreased beginning accumulated deficit by $15.1 million.
The following table provides the impact of adopting the guidance on the Company’s financial statements:
Three months Ended March 31, 2019Nine months Ended March 31, 2019
(Dollars in millions)As ReportedEffects of ChangeAmount without Adoption of ASC 606As ReportedEffects of ChangeAmount without Adoption of ASC 606
Net revenue$617.5 $23.6 $641.1 $1,792.3 $40.2 $1,832.5 
Cost of sales418.8 21.8 440.6 1,243.7 52.4 1,296.1 
Gross margin198.7 1.8 200.5 548.6 (12.2)536.4 
Earnings from continuing operations before income taxes 42.6 1.8 44.4 80.5 (12.2)68.3 
Income tax expense10.9 (0.2)10.7 14.2 (4.0)10.2 
Net earnings/(loss)$31.7 $2.0 $33.7 $66.3 $(8.2)$58.1 
The impact of ASC 606 on the Company's consolidated balance sheet is immaterial.
The adoption of ASC 606 resulted in three primary changes as compared to the previous revenue recognition guidance: (a) revenue from commercial product supply is recognized following successful completion of the required quality assurance process where it was previously recognized upon shipment of the product to the customer; (b) earlier recognition of revenue from certain commercial supply contract cancellations is recognized as variable consideration as the Company’s performance obligations are satisfied rather than only upon agreement of the amount with the customer; and (c) revenue from sourcing comparator drug product for clinical supply services is recorded net of the cost of procuring it rather than at full value with a corresponding expense. Refer to Note 2 for the Company's revenue recognition policy.
In March 2017, the FASB issued ASU 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which requires entities to report the service cost component of the net periodic benefit cost in the same income statement line as other compensation costs arising from services rendered by employees during the reporting period. The other components of the net benefit costs will be presented in the income statement separately from the service cost and below the income from operations subtotal. The Company adopted this guidance as of July 1, 2018, on a retrospective basis, which had an effect on the consolidated statement of operations for the three and nine months ended March 31, 2018. The following table summarizes the Company's As Previously Reported and As Adjusted changes to the consolidated statement of operations for the three and nine months ended March 31, 2018:
14

Table of Contents
Three Months Ended March 31, 2018Nine Months Ended March 31, 2018
(Dollars in millions)As Previously ReportedAs AdjustedAs Previously ReportedAs Adjusted
Selling, general, and administrative expenses$117.0 $117.6 $338.3 $339.9 
Operating earnings73.1 72.5 173.8 172.2 
Other expense, net10.5 9.9 29.8 28.2 
In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which reduces the complexity of and simplifies the application of hedge accounting by issuers. The ASU is effective for fiscal years beginning after December 15, 2018 and interim periods within those years. Early adoption is permitted. The Company early adopted this guidance as of July 1, 2018 on a prospective basis. The adoption of this guidance was not material to the Company's consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when an entity will apply modification accounting for changes to stock-based compensation arrangements. Modification accounting applies if the value, vesting conditions, or classification of an award changes. The Company adopted this guidance prospectively at the beginning of fiscal 2019. The adoption of this guidance was not material to the Company's consolidated financial statements.
In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which provides additional guidance on the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The Company adopted this guidance prospectively at the beginning of fiscal 2019. The adoption of this guidance was not material to the Company's consolidated financial statements.
In January 2016, the FASB issued ASU 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which changes the accounting for equity investments and financial liabilities under the fair value option, and presentation and disclosure requirements for financial instruments. The ASU requires equity investments with readily determinable fair values to be measured at fair value and to recognize change in fair value in net earnings. The ASU is not applicable to equity investments accounted for under the equity method of accounting or those that result in consolidation of the investee. The Company adopted this guidance at the beginning of fiscal 2019. The adoption of this guidance was not material to the Company's consolidated financial statements.
New Accounting Standards Not Adopted as of March 31, 2019
In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies that certain transaction between participants in a collaboration arrangement should be accounted for under ASC 606 when the counterparty is a customer. The guidance also precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The ASU will be effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years and should be applied retrospectively. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.
In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The ASU will be effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years and allows for either a retrospective or prospective application. The Company does not expect the adoption of the guidance to have a material impact to its consolidated financial statements.
In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which permits an entity to reclassify to retained earnings the stranded tax effects caused by the Tax Cuts and Jobs Act of 2017 on items within accumulated other comprehensive income/(loss). The ASU will be effective for fiscal years beginning after December 15, 2018 and interim periods within those years. Early adoption is permitted. The Company does not expect the adoption of the guidance to have a material impact to its consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduces a new accounting model known as Credit Expected Credit Losses 
15

Table of Contents
("CECL"). CECL requires earlier recognition of credit losses, while also providing additional transparency about credit risk. The CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses for receivables at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. This model replaces the multiple existing impairment models in current GAAP, which generally require that a loss be incurred before it is recognized. The new standard will also apply to receivables arising from revenue transactions such as contract assets and accounts receivables. The ASU will be effective for fiscal years beginning after December 15, 2019. The Company does not expect the adoption of the guidance to have a material impact to its consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which will supersede ASC 840 Leases. The new guidance requires lessees to recognize most leases on their balance sheets for the rights and obligations created by those leases. The guidance requires enhanced disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases and will be effective for public reporting entities in annual reporting periods beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The guidance is required to be adopted using the modified retrospective approach. The Company will adopt the guidance on July 1, 2019, and anticipates that most of its operating leases will result in the recognition of additional assets and corresponding liabilities on its consolidated balance sheets. The Company will elect the transition method that allows for the application of the standard at the adoption date rather than at the beginning of the earliest comparative period presented in the financial statements. The Company has selected a lease accounting tool and made progress in validating lease data validation for contracts that are in the Company's current lease portfolio and continues to assess the impact of embedded leases in certain agreements.
2. REVENUE RECOGNITION
The Company recognizes revenue in accordance with ASC 606. The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party.
The company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material.
The following tables allocate revenue for the three and nine months ended March 31, 2019 by type of activity and reporting segment (in millions):
Three months ended March 31, 2019 Softgel TechnologiesBiologics & Specialty Drug DeliveryOral Drug DeliveryClinical Supply ServicesTotal
Manufacturing & commercial product supply$200.2 $97.8 $107.7 $ $405.7 
Development services14.3 74.3 54.0  142.6 
Clinical supply services   77.8 77.8 
Total$214.5 $172.1 $161.7 $77.8 $626.1 
Inter-segment revenue elimination(8.6)
Combined net revenue$617.5 

Nine months ended March 31, 2019 Softgel TechnologiesBiologics & Specialty Drug DeliveryOral Drug DeliveryClinical Supply ServicesTotal
Manufacturing & commercial product supply$581.6 $260.2 $289.9 $ $1,131.7 
Development services45.8 250.8 155.9  452.5 
Clinical supply services   236.3 236.3 
Total$627.4 $511.0 $445.8 $236.3 $1,820.5 
Inter-segment revenue elimination(28.2)
Combined net revenue$1,792.3 

16

Table of Contents
The following table allocates revenue by the location where the goods were made or the service performed:
(Dollars in millions)Three months ended March 31, 2019Nine months ended March 31, 2019
United States$318.4 $913.9 
Europe200.8 609.9 
International Other108.2 321.6 
Elimination of revenue attributable to multiple locations(9.9)(53.1)
Total$617.5 $1,792.3 
Manufacturing & Commercial Product Supply Revenue
Manufacturing and commercial product supply revenue consists of revenue earned by manufacturing products supplied to customers under long-term commercial supply arrangements. The Company recognizes revenue for manufacturing and supplying commercial products as control is transferred to the customer, which is measured based on product that has successfully completed contractually required quality assurance process. Revenue is measured based on the amount of consideration the Company expects to receive in exchange for providing these products and services. The contractual performance obligation generally includes manufacture and the completion of product quality release testing procedures specified in the contract. These activities are interdependent and thus are considered to be a single combined performance obligation. Payment is typically due 30 to 90 days after the goods are shipped to the customer based on the payment terms set forth in the applicable customer agreement.
Development Services Revenue
Development services contracts generally take the form of short-term, fee-for-service arrangements. Performance obligations vary, but frequently include (1) the delivery of a formulation report, analytical and stability testing report, or other report on product- or molecule-based studies or (2) the manufacture of products under development or otherwise not intended for commercial sale. The transaction prices for these arrangements include fixed consideration of the amounts stated in the contracts for each promised good or service, which are generally considered to be separate performance obligations. The Company recognizes revenue when or as control of each individual performance obligation is transferred to the customer and exercises judgment in determining the timing of revenue recognition by analyzing the point in time or period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the arrangement. Control generally transfers to the customer when services have been completed or the customer has accepted the product or service deliverable and the Company has right to payment based on the terms of the agreement.
In certain arrangements, the Company recognizes revenue over time as the Company satisfies performance obligations. Satisfaction of the performance obligations is measured using an output method measure of progress based on effort expended by the Company. In other arrangements, revenue is recognized when the customer has taken legal title to or accepted the product or service deliverable and the Company has a right to payment based on the terms of the arrangement.
Development services contracts may also include certain success-based milestone payments for completed performance obligations, such as regulatory approval and product validation prior to the commencement of commercial supply. Revenue associated with developmental milestones is considered variable consideration and is typically recognized when the success-based milestone is achieved, and no significant revenue reversal is anticipated.
The Company allocates consideration to each performance obligation based on the relative selling price. Payment is typically due 30 to 90 days following the completion of services provided to the customer based on the payment terms set forth in the applicable customer agreement. Certain development service arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract and is initially recorded as a contract liability.
Clinical Supply Services Revenue
Clinical supply services contracts generally take the form of fee-for-service arrangements. Performance obligations for clinical supply services revenue typically include a combination of the following services: the manufacturing, packaging, storage, distribution, destruction, and inventory management of customer clinical trials materials. Performance obligations can also include the sourcing of comparator drug products on behalf of customers to be used in clinical trials to compare performance with the drug under clinical investigation. In certain arrangements, the Company recognizes revenue over time when the Company satisfies performance obligations. Satisfaction of the performance obligations is measured using an output method measure of progress based on effort expended by the Company. In other arrangements, revenue is recognized when the customer has taken legal title or accepted the product or service deliverable and the Company has right to payment based on the
17

Table of Contents
terms of the arrangement. Payment is typically due 30 to 90 days following the completion of services provided to the customer based on the payment terms set forth in the applicable customer agreement.
The Company records revenue for comparator sourcing arrangements on a net basis because it is acting as an agent that does not control the product or service before it is transferred to the customer. Payment for comparator sourcing activity is typically received in advance at the commencement of the contract and is initially recorded as a contract liability.
Contract Liabilities
Contract liabilities relate to cash consideration that the Company receives in advance of satisfying the related performance obligations. Changes in the contractual liabilities balance during the nine months ended March 31, 2019 are as follows:
(Dollars in millions)
Contract liability
Balance at June 30, 2018$100.9 
Balance at March 31, 2019$106.9 
Revenue recognized in the period from:
Amounts included in contracts liability at the beginning of the period$53.4 
Remaining Performance Obligations
For the Softgel Technologies, Biologics and Specialty Drug Delivery, and Oral Drug Delivery segments, remaining performance obligations represent firm orders for manufacturing and commercial product supply, including minimum volume commitments and future development services, for which there are incomplete performance obligations. For the Clinical Supply Services segment, remaining performance obligations represent estimated future service revenues from work not yet completed under signed contracts. The remaining performance obligations as of March 31, 2019 were $1,327.9 million, including approximately $346.2 million related to our Clinical Supply Services segment. We expect to recognize approximately 47% of the remaining performance obligations in existence as of March 31, 2019 over the next three months, with the remaining recognized thereafter. 

3. BUSINESS COMBINATIONS
Juniper Pharmaceuticals Acquisition
On August 14, 2018, Operating Company acquired Juniper Pharmaceuticals, Inc., a Delaware corporation ("Juniper") through a tender offer and back-end merger, pursuant to the terms of an agreement and plan of merger (the "Juniper Merger Agreement"), and Juniper became a wholly owned subsidiary of Operating Company. Under the terms of the Juniper Merger Agreement, all outstanding options to purchase Juniper shares were canceled in exchange for cash equal to the product of the number of Juniper shares subject to the option and the difference between the price per share paid in the tender offer and the exercise price. Similarly, all outstanding restricted stock units in respect of Juniper shares were canceled in exchange for cash equal to the product of the number of units and the price per share paid in the tender offer. Juniper has expertise in formulation development and supply and augments the Company's pre-existing portfolio of solid-state screening, pre-formulation, formulation, analytical, and bioavailability enhancement solutions, including the development of drug products produced using spray-dried dispersion, with integrated development, analytical, and clinical manufacturing. Juniper also owns the ex-U.S. rights to and supplies for sale to its licensee of such rights CRINONE®, a reproductive therapy. The primary operations of the acquired business are located in owned facilities aggregating 38,000 square feet in Nottingham, U.K. and is now included in the Oral Drug Delivery segment. Results of this segment include the results of Juniper for the period since the acquisition.
The aggregate purchase consideration, net of cash acquired, of $127.5 million was funded by cash on hand. As a result of the preliminary fair value allocations, the Company recognized intangible assets of $69.0 million and $11.0 million for product relationships and customer relationships, respectively. The remainder of the preliminary fair value was allocated to tangible assets acquired and goodwill. The fair value allocation is expected to be completed upon finalization of an independent appraisal over the next several months, but no later than one year from the acquisition date.
18

Table of Contents
4. GOODWILL
The following table summarizes the changes between June 30, 2018 and March 31, 2019 in the carrying amount of goodwill in total and by reporting segment:
(Dollars in millions)Softgel TechnologiesBiologics and Specialty Drug DeliveryOral Drug DeliveryClinical Supply ServicesTotal
Balance at June 30, 2018$415.2 $505.7 $319.9 $156.4 $1,397.2 
Additions  23.6  23.6 
Foreign currency translation adjustments(8.4)(1.4)(1.1)(0.6)(11.5)
Balance at March 31, 2019$406.8 $504.3 $342.4 $155.8 $1,409.3 
The increase in goodwill in the Oral Drug Delivery reporting segment is a result of the Juniper acquisition. The Company did not record an impairment charge in the current period. 
5. DEFINITE-LIVED LONG-LIVED ASSETS
The Company’s definite-lived long-lived assets include property, plant, and equipment as well as intangible assets with definite lives. Refer to Note 16, Supplemental Balance Sheet Information for details related to property, plant, and equipment.
The details of other intangibles, net as of March 31, 2019 and June 30, 2018 are as follows:
(Dollars in millions)Weighted Average Life
Gross
Carrying
Value
Accumulated
Amortization
Net
Carrying
Value
March 31, 2019
Amortized intangibles:
Core technology18 years$168.9 $(104.1)$64.8 
Customer relationships14 years597.5 (171.7)425.8 
Product relationships11 years277.8 (214.0)63.8 
Total intangible assets$1,044.2 $(489.8)$554.4 

The increases in customer relationships and product relationships as of March 31, 2019 are associated with the acquisition of Juniper in August 2018.
(Dollars in millions)Weighted Average Life
Gross
Carrying
Value
Accumulated
Amortization
Net
Carrying
Value
June 30, 2018
Amortized intangibles:
Core technology18 years$170.8 $(85.3)$85.5 
Customer relationships14 years587.0 (140.9)446.1 
Product relationships12 years210.5 (197.2)13.3 
Total intangible assets$968.3 $(423.4)$544.9 

Amortization expense was $31.4 million and $69.1 million for the three and nine months ended March 31, 2019, respectively, and $17.6 million and $45.1 million for the three and nine months ended March 31, 2018, respectively. During the three months ended March 31, 2019, the Company recorded $12.3 million of accelerated amortization related to a product participation licensing right. Future amortization expense for the next five fiscal years is estimated to be:
(Dollars in millions)Remainder 
Fiscal 2019
20202021202220232024